Optimising anti-TNF treatment using biosimilars
Inadequate response to initial anti-TNF therapy in RA
Inadequate response to initial anti-TNF therapy in RA
When is a switch of therapies warranted in managing RA with anti-tumour necrosis factor (TNF) treatment? Patient care involves more than selecting the appropriate treatment, but should also consider numerous additional factors, from comorbidities to patient preferences. Review primary goals of RA treatment, EULAR recommendation, and more in this infographic overview.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently of the sponsors who have had no editorial input into the content. Medthority received educational funding from the sponsor Biogen in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.